Clinical Trial

Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this exploratory study is to evaluate the effect of neflamapimod in participants with nonfluent variant primary progressive aphasia (nfvPPA). We aim to evaluate the safety, pharmacokinetics and clinical effects of neflamapimod of participants with nfvPPA.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-07
Trial Details
NCT Number NCT07033481
Lead Sponsor EIP Pharma Inc
Collaborators: CervoMed, Inc.
Conditions Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
Enrollment 20 participants
Start Date 2025-10-02
Primary Completion 2026-09 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-06